Search | Clinical Trials Finder

Conditions: Thrombosis, Cancer, Pulmonary Embolism
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more

Conditions: Acute Coronary Syndrome
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 7,484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 221
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin + Placebo, Apixaban + Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 3,608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more

Conditions: Atrial Fibrillation (AF)
Interventions: REGN7508, Apixaban, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15,364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Dothan, Alabama • Newport Beach, California • Pasadena, California + 5 more

Conditions: Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bleeding
Interventions: Andexanet, Placebo; Biological · Other
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bleeding
Interventions: Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Venous Thrombosis, Pulmonary Embolism
Interventions: Apixaban, Enoxaparin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 40 Years and older
Enrollment: 6,758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more

Conditions: Healthy Volunteers
Interventions: PRT064445/Apixaban, Placebo/Apixaban, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bleeding
Interventions: Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions: Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14,830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 163
States / cities: Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more

Conditions: Covid19
Interventions: Apixaban 2.5 MG, Placebo; Drug
Lead sponsor: Thomas L. Ortel; Other
Eligibility: 18 Years and older
Enrollment: 1,291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 121
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more

Conditions: Acute Coronary Syndromes
Interventions: Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 143
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more

Conditions: Wound Bleeding
Interventions: BXP154B, Placebo, Punch Biopsy; Drug · Procedure
Lead sponsor: Bio 54, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Nirmish Shah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Venous Thrombosis
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 2,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more

Conditions: Acute Coronary Syndrome (ACS)
Interventions: Apixaban, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more

Conditions: Atrial Fibrillation
Interventions: Milvexian, Apixaban, Placebo, Apixaban Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 20,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 216
States / cities: Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more

Conditions: Acute Ischemic Stroke
Interventions: LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran; Drug
Lead sponsor: Lumosa Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Apixaban; Drug
Lead sponsor: Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Venous Thrombosis, Pulmonary Embolism
Interventions: Apixaban, Enoxaparin, Warfarin, Enoxaparin Placebo, Apixaban Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 69 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Apixaban 2.5 MG, Placebo oral tablet; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device); Drug · Device
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more

Search by objective public record fields.

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

Phase III Acute Coronary Syndrome

Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B

Apixaban in Patients With Sickle Cell Disease

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Safety Study of Apixaban in Recent Acute Coronary Syndrome

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)